# Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

> **NCT04484818** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 27 (actual)

## Conditions studied

- Prostate Carcinoma

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Goserelin Acetate
- **DRUG:** Leuprolide Acetate
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Triptorelin

## Key facts

- **NCT ID:** NCT04484818
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-05-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484818, "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04484818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*